Feb
9
2021
On demand

Supporting development of mRNA-based therapies by addressing large scale purification challenges

The field of mRNA-based therapies is rapidly evolving. The potential of these therapies has been demonstrated in various fields such as cancer vaccines, tumor immunotherapy and more recently, gene editing and vaccine development. Although the potential of mRNA in therapies seems to be endless, obtaining larger quantities of synthetic mRNA for clinical treatment remains a challenge. The current available methods for mRNA purification are becoming a bottleneck in large-scale manufacturing.

Affinity chromatography, a highly scalable method, has earned its credits in the development of biologics such as the use of Protein A for the purification of therapeutic antibodies and more recently, anti-AAV resins in gene therapy workflows. An effective affinity purification step can help to simplify biomolecule downstream processing, reduce the number of purification steps, and reduce the overall cost of goods in bio-therapeutic manufacturing. To support the development of mRNA-based therapies, we have developed a new affinity resin for the purification and isolation of mRNA from in vitro transcription (IVT) manufacturing processes. This webinar will provide an overview on how this resin can help to maximize efficiency and simplify the mRNA purification process.

Attendees will: 

  • Understand how affinity chromatography can help to simplify workflows and maximize efficiency of your mRNA purification process 
  • Learn more about the new Thermo Fisher Scientific™ POROS™ Oligo (dT)25 affinity chromatography resin for the purification of IVT mRNA

Kelly Flook, PhD

Senior Product Manager, Purification, Bioproduction Division, Thermo Fisher Scientific

Kelly Flook is Senior Product Manager for Purification products within the Bioproduction Division at Thermo Fisher Scientific. Kelly has a Ph.D in Polymer and Analytical Chemistry from the University of Durham, UK. During her 15 years at Thermo Fisher, Kelly has gained extensive experience in product development across all scales of chromatography and related biological workflows. Kelly has a strong expertise in bead technology and bio-separations. Drawing from a diverse technical background, in her current role Kelly is responsible for new product development and commercialization of solutions across the downstream workflow.

SPEAKERS

Kelly Flook
Senior Product Manager, Purification, Bioproduction Division, Thermofisher scientific

You might also like

Thinking translational: Things to consider in CAR T cell research workflows

S Rösch, PhD
Saskia Rösch, PhD
Saskia Rösch, PhD
Global Product Manager at Miltenyi Biotec
22 Jun 2022
34
Days
23
Hrs
16
Min
Register

Accelerating cell therapy discovery & development with non-viral gene...

D Hermanson
X Patrinostro
David Hermanson
David Hermanson
Senior Manager of R&D Applications, Cell and Gene Therapy at Bio-techne
Xiaobai Patrinostro
Xiaobai Patrinostro
Manager of Genome Engineering Services, Cell and Gene Therapy at Bio-techne
16 Jun 2022
28
Days
7
Hrs
16
Min
Register

Optimizing mRNA purification conditions by using a Design of Experiments...

J England
Jenny England
Jenny England
Application Scientist and Innovation Leader at Thermo Fisher Scientific
14 Jun 2022
26
Days
23
Hrs
16
Min
Register

Taking a right first-time approach to optimize end-to-end viral vector...

H Lesch
J Depollier
Hanna Lesch
Hanna Lesch
Chief Technology Officer at Exothera
Julien Depollier
Julien Depollier
Business Director, Americas at Polyplus-transfection
9 Jun 2022
21
Days
23
Hrs
16
Min
Register

Applying an HPLC analytical platform for mRNA process monitoring

N Pavlin
Nejc Pavlin
Nejc Pavlin
Project Manager in Process Analytics Development at BIA Separations
7 Jun 2022
19
Days
23
Hrs
16
Min
Register